Rigel Pharmaceuticals Appoints New Chief Medical Officer
Ticker: RIGL · Form: 8-K · Filed: Sep 19, 2024 · CIK: 1034842
| Field | Detail |
|---|---|
| Company | Rigel Pharmaceuticals Inc (RIGL) |
| Form Type | 8-K |
| Filed Date | Sep 19, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel-change, biotech
Related Tickers: VERA
TL;DR
Rigel just hired a new CMO, Dr. Castro, from Verastem. Big move for their pipeline.
AI Summary
Rigel Pharmaceuticals, Inc. announced on September 16, 2024, the appointment of Dr. V. Michael B. B. Castro as Chief Medical Officer. Dr. Castro previously served as Senior Vice President and Chief Medical Officer at Verastem Oncology, where he played a key role in advancing their pipeline. This appointment is part of Rigel's ongoing efforts to strengthen its leadership team.
Why It Matters
The appointment of a new Chief Medical Officer can signal a strategic shift or renewed focus on clinical development and regulatory strategy for Rigel's drug pipeline.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially the Chief Medical Officer, can indicate shifts in strategy or potential challenges in clinical development, impacting the company's future prospects.
Key Players & Entities
- Rigel Pharmaceuticals, Inc. (company) — Registrant
- Dr. V. Michael B. B. Castro (person) — Newly appointed Chief Medical Officer
- Verastem Oncology (company) — Previous employer of Dr. Castro
- September 16, 2024 (date) — Date of earliest event reported
FAQ
What is the effective date of Dr. Castro's appointment as Chief Medical Officer?
The filing indicates that September 16, 2024, is the date of the earliest event reported, which includes the appointment of certain officers.
What was Dr. Castro's previous role before joining Rigel Pharmaceuticals?
Dr. Castro previously served as Senior Vice President and Chief Medical Officer at Verastem Oncology.
What is Rigel Pharmaceuticals' primary business?
Rigel Pharmaceuticals, Inc. is in the business of Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].
Where is Rigel Pharmaceuticals headquartered?
Rigel Pharmaceuticals, Inc. is headquartered at 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080.
What is the Commission File Number for Rigel Pharmaceuticals?
The Commission File Number for Rigel Pharmaceuticals, Inc. is 000-29889.
Filing Stats: 486 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-09-19 16:01:11
Key Financial Figures
- $0.001 — h Registered Common Stock, par value $0.001 per share RIGL The Nasdaq Stock Mar
Filing Documents
- tm2424205d1_8k.htm (8-K) — 22KB
- 0001104659-24-101327.txt ( ) — 191KB
- rigl-20240916.xsd (EX-101.SCH) — 3KB
- rigl-20240916_lab.xml (EX-101.LAB) — 33KB
- rigl-20240916_pre.xml (EX-101.PRE) — 22KB
- tm2424205d1_8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 19, 2024 RIGEL PHARMACEUTICALS, INC. By: /s/ Raymond J. Furey Raymond J. Furey Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary